Shuttle Pharmaceuticals (NASDAQ:SHPH) Shares Down 1.8% – Time to Sell?

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH)’s stock price was down 1.8% during mid-day trading on Monday . The company traded as low as $0.7006 and last traded at $0.7450. Approximately 133,925 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 248,883 shares. The stock had previously closed at $0.7590.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Stock Down 1.8%

The company has a market cap of $1.19 million, a PE ratio of -0.06 and a beta of -0.53. The stock has a 50-day simple moving average of $1.13 and a 200 day simple moving average of $2.04.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its earnings results on Tuesday, March 31st. The company reported $0.06 EPS for the quarter.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SHPH. Geode Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at $26,000. Boothbay Fund Management LLC purchased a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at $37,000. Ikarian Capital LLC purchased a new stake in Shuttle Pharmaceuticals in the fourth quarter valued at $124,000. Finally, Connective Capital Management LLC purchased a new stake in Shuttle Pharmaceuticals in the third quarter valued at $357,000. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .